BRIEF published on 04/07/2026 at 07:05, 5 months 20 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 5 months 20 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 6 months 6 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
PRESS RELEASE published on 03/21/2026 at 10:05, 6 months 6 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 8 months 15 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
BRIEF published on 12/02/2025 at 07:05, 9 months 25 days ago Aelis Farma launches a Phase 2B clinical trial for AEF0217 in people with Down syndrome Clinical Trial Aelis Farma CB1-SSi AEF0217 Down Syndrome
BRIEF published on 09/25/2025 at 22:20, 1 year ago Availability of the 2025 half-year financial report by Aelis Farma Financial Report Biopharmaceuticals Aelis Farma Medical Innovations CB1-SSi
PRESS RELEASE published on 09/25/2025 at 22:15, 1 year ago Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report Aelis Farma announces availability of 2025 half-year financial report. Company specializes in CB1 receptor treatments for brain and peripheral diseases Financial Report Aelis Farma CB1 Receptor Brain Diseases Peripheral Diseases
BRIEF published on 07/31/2024 at 10:02, 2 years 1 month ago Aelis Farma successfully raises 4.5 million euros Euronext Paris Investors Fundraising Biopharmaceutical Aelis Farma
PRESS RELEASE published on 07/31/2024 at 09:57, 2 years 1 month ago Inside Information / Other news releases Aelis Farma successfully completes Reserved Offering, raising €4.5 million for drug development. CEO expresses gratitude to investors. New shares to be admitted for trading on Euronext Paris on Aug 2, 2024 Euronext Paris Capital Increase Drug Development Aelis Farma Reserved Offering
Published on 09/26/2026 at 01:00, 1 day 19 hours ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 1 day 22 hours ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 2 days 3 hours ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 2 days 5 hours ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/27/2026 at 17:05, 3 hours 30 minutes ago Saudi Tourism Authority Concludes Monaco Yacht Show 2026 with Major Milestones for Saudi Red Sea Yachting
Published on 09/26/2026 at 15:30, 1 day 5 hours ago QUORRA X5 Makes Its Global Debut at REHACARE International 2026 in Germany
Published on 09/26/2026 at 15:15, 1 day 5 hours ago Timur Turlov Elected FIDE President, Becomes First Kazakh to Lead World Chess
Published on 09/26/2026 at 07:45, 1 day 12 hours ago Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 1 day 20 hours ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 17:40, 2 days 2 hours ago Availability of the 2026 half-year financial report
Published on 09/24/2026 at 18:00, 3 days 2 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 3 days 2 hours ago GUILLEMOT CORPORATION: 2026 CONSOLIDATED INTERIM RESULTS
Published on 09/24/2026 at 17:45, 3 days 2 hours ago Cegedim first-half 2026 results: profitability continues to improve
